A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Itepekimab (Primary) ; Mometasone
- Indications Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms CEREN2
- Sponsors Sanofi
Most Recent Events
- 26 Feb 2025 New trial record